Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cinqair

(Reslizumab)

PreclinicalMonoclonal antibody

Reslizumab is used to treat a specific type of severe asthma in adults and children where the body produces too many of a certain type of white blood cell called eosinophils, which cause airway inflammation and breathing problems.[1] Cinqair is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]

Cinqair is one of 29 small molecule programs targeting Airway obstruction. It is currently in Preclinical.

1

Indications

22

Total Trials

0

Active Trials

28

Competitors

3

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Airway ObstructionUnknown

Airway ObstructionPreclinical

Unknown

Competition

Competitive Landscape

31 competitors in Airway Obstruction

#DrugCompanyPhaseTrials

Brethine

Theo-Dur

Daliresp

Onbrez

Adrenaline

SSamson Clinical Operations Pty Ltd

Kenalog

BBassett Healthcare

Foradil

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Alvesco

AAzurity Pharmaceuticals

Celestone

SSchering-Plough

Qvar

SSchering-Plough

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma13 trials

Similarities and Differences of Biological Therapies for Severe Asthma.

Unknown status·—··NCT04665141·600 enrolled

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Completed· Teva logo

Teva·Phase 3·NCT01270464·315 enrolled

Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

Completed·MMcMaster University·Phase 2/3·NCT02559791·10 enrolled

Show 10 more trials

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Completed· Teva logo

Teva·Phase 3·NCT02501629·177 enrolled

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Completed· Teva logo

Teva·Phase 3·NCT01287039·489 enrolled

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

Completed·MMcMaster University·Phase 4·NCT04710134·10 enrolled

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Completed· Teva logo

Teva·Phase 3·NCT02452190·468 enrolled

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Completed·CCeption Therapeutics·Phase 2·NCT00587288·106 enrolled

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Completed· Teva logo

Teva·Phase 3·NCT01285323·464 enrolled

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Terminated· Teva logo

Teva·Phase 3·NCT01290887·1,052 enrolled

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Completed· Teva logo

Teva·Phase 3·NCT01508936·511 enrolled

Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab

Completed·SSociedad Española de Neumología y Cirugía Torácica·Phase 2·NCT03074942·30 enrolled

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Terminated· Teva logo

Teva·Phase 3·NCT03052725·391 enrolled

Chronic Rhinosinusitis2 trials

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

Withdrawn·UUniversity of Rochester··NCT03369574

Effect of Reslizumab in Chronic Rhinosinusitis

Unknown status·—·Phase 3·NCT02799446·30 enrolled

Eosinophilic Esophagitis2 trials

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Completed·CCeption Therapeutics·Phase 3·NCT00635089·190 enrolled

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Completed·CCeption Therapeutics·Phase 2/3·NCT00538434·227 enrolled

Interleukin1 trial

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

Completed·FFood and Drug Administration (FDA)·Phase 1·NCT04183192·72 enrolled

Granulomatosis with Polyangiitis1 trial

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Unknown status·NNational Jewish Health·Phase 2·NCT02947945·10 enrolled

3 more indications

Loiasis1 trial

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01111305·31 enrolled

Inflammation1 trial

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Terminated· Teva logo

Teva·Phase 4·NCT02937168·5 enrolled

Unspecified1 trial

Absolute Bioavailability of Reslizumab in Healthy Subjects

Completed· Teva logo

Teva·Phase 1·NCT01990443·75 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 23, 2016

CINQAIR

BLA BLA761033

Mar 23, 2016

CINQAIR

NDA BLA761033

Jan 9, 2019

CINQAIR

NDA BLA761033

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Reslizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Reslizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Reslizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA BLA761033). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-5 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: Teva

Related News